Litigation Details for AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)
✉ Email this page to a colleague
AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-10-30 |
| Court | District Court, D. Delaware | Date Terminated | 2018-11-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | HEC PHARM CO. LTD. | ||
| Patents | 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934; RE46,276 | ||
| Attorneys | Barry P. Golob | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca LP v. Mylan Pharmaceuticals Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for AstraZeneca LP v. Mylan Pharmaceuticals Inc. (D. Del. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2015-10-30 | 1 | Complaint | AstraZeneca’s U.S. Patent Nos. 6,251,910 (“the ’910 patent”), 6,525,060 (“the ’060 patent”), 7,250,419 (… (“the ’419 patent”), 7,265,124 (“the ’124 patent”), and 8,425,934 (“the ’934 patent”) ME1 21394971v… This is an action for patent infringement arising under the patent laws of the United States, … PATENTS-IN-SUIT 21. On June 26, 2001, the U.S. Patent and Trademark Office…copy of the ’910 patent is attached hereto as Exhibit A. The claims of the ’910 patent are valid and enforceable | External link to document |
| 2016-09-06 | 129 | Redacted Document | .S. Patent Nos. 7,265,124 ("'124 Patent") and 8,425,934 ("'934 Patent"…July 20, 2015, HEC Pharm Co., Ltd. filed a Patent Certification with ANDA No. 208508, certifying …quot;) (collectively, "Patents-in-Suit") are invalid, unenforceable or will not be infringed…"; D.I. 1), asserting infringement of the Patents-in-Suit under 35 U.S.C. § 271(e)(2)(A); …, asserting affirmative defenses regarding the Patents-in-Suit, as well as counterclaims for declaratory | External link to document |
| 2017-02-20 | 165 | Memorandum Opinion | of multiple terms in U.S. Patent Nos. 6,525,060 ("the '060 patent") and 7,265,124 ("…construction for multiple terms in U.S. Patent Nos. 6,525,060 and 7,265,124. Signed by Judge Richard G…U.S. Patent No. RE46,276 ("the '276 patent"). The '060 and '276 patents share…infringe five of AstraZeneca's patents. (D.I. 1). 2 The patents-in-suit claim chemical compounds as…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which | External link to document |
| 2017-02-24 | 168 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 7,250,419; 7,265,124… 29 November 2018 1:15-cv-01000 830 Patent None District Court, D. Delaware | External link to document |
| 2017-03-15 | 172 | Patent/Trademark Report to Commissioner | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,250,419; 7,265,124; RE 46,276… 29 November 2018 1:15-cv-01000 830 Patent None District Court, D. Delaware | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
